Develops engineered, donor-derived immune-cell therapies for people with autoimmune diseases and cancer.
10-K for FY2025, filed Mar 12, 2026
Revenue comes from fixed fees at agreement start and specified future dates, milestone payments when specified events occur, and royalties on licensed-product sales. Upfront license fees are tied to when the partner can use the intellectual property; bundled licenses and research services can generate revenue over time or at a specific point.
10-K for FY2025, filed Mar 12, 2026The Company recognizes revenue under the Companyโs license or collaboration agreements that are within the scope of ASC 606. TheseโฆView โ
$5.8M
10-K for FY2025, filed Mar 12, 2026
$5.8M โ
Companies work with Adicet through license and collaboration agreements covering intellectual-property licenses and research and development services.
10-K for FY2025, filed Mar 12, 2026
No. It lost $116.8M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
โ$18.9MView โ
Shrinking. Revenue fell 41% in 4 years, from $9.8M in FY2021 to $5.8M in FY2025, about 12% a year.
Expanded focus to autoimmune diseases
The earlier report described the companyโs therapies and pipeline as focused on cancer. The latest report includes autoimmune diseases alongside cancer, with prula-cel being developed for autoimmune conditions.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 12, 2026
Competes with Kite Pharma and Novartis
10-K for FY2025, filed Mar 12, 2026Autologous cell therapies, such as those developed by Kite Pharma and Novartis, have a number of limitations, including but not limited toโฆView โ
Loading...